{
  "pmcid": "9994847",
  "sha256": "bc1f0dd3e20bca1c5053111b20b11fb6530c5c3e627acd1a6e200641b348d744",
  "timestamp_utc": "2025-11-10T00:14:13.595472+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.724263565891473,
    "reading_ease": 42.36401808785533,
    "word_count": 258
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Neoadjuvant Chemotherapy vs. Chemoradiotherapy in Locally Advanced Rectal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "663 patients with LARC within 12 cm from the anal verge and uninvolved MRF were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "663 patients with LARC within 12 cm from the anal verge and uninvolved MRF"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to nCT (4 cycles of CAPOX) or nCRT (capecitabine with 50 Gy radiation)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates neoadjuvant chemotherapy (nCT) as an alternative in lower-risk locally advanced rectal cancer (LARC)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was 3-year local-regional failure-free survival"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was stratified by tumor location and nodal staging, with allocation concealment via central randomisation"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between June 2014 and October 2020, 589 patients received treatment (nCT: 300, nCRT: 289)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "589 patients received treatment (nCT: 300, nCRT: 289)"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "pCR rates were 11.0% (95% CI, 7.8-15.3%) for nCT and 13.8% (95% CI, 10.1-18.5%) for nCRT (p=0.33)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with grade 3-4 toxicities in 12.3% of nCT and 8.3% of nCRT patients (p=0.11)"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02288195"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}